-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals
only, do you know who is at highest risk of aggressive prostate cancer?
fatal prostate cancer.
Study screenshots
each year.
In the United States, the lifetime risk of being diagnosed with prostate cancer is about 11 percent, and the lifetime risk of dying from prostate cancer is about 2.
5 percent
.
Meghana S.
Pagadala, MD, of the Medical Scientist Training Program at the University of California, San Diego School of Medicine, said
The most common prostate cancer screening test is the prostate-specific antigen (PSA) test, which measures the level of a protein in the
blood.
Higher PSA levels in the blood may indicate prostate cancer, but a number of other factors can also affect PSA levels, screening everyone may lead to unnecessary biopsies, as well as the diagnosis and treatment
of low-grade cancers that do not pose a serious threat.
Tyler M.
Seibert, MD, assistant professor in the Department of Radiation Medicine and Applied Science, Radiology and Bioengineering at the University of California, San Diego School of Medicine, said
risk of prostate cancer.
The median age at last follow-up was 69 years
.
In all cohort studies, PHS290 was associated with fatal prostate cancer (p<0.
001).
<b20> Comparing the 20% of men with the highest PHS290 levels to the 20% of men with the lowest PHS290 levels, the hazard ratio for fatal prostate cancer was 4.
42
.
When considering the risk factors recommended by the guidelines (family history, race, and ethnicity), PHS290 remains a strong independent predictor
of various metastatic and fatal prostate cancers.
Seibert, MD, said:
only, do you know who is at highest risk of aggressive prostate cancer?
Executive Summary
fatal prostate cancer.
Study screenshots
status quo
each year.
In the United States, the lifetime risk of being diagnosed with prostate cancer is about 11 percent, and the lifetime risk of dying from prostate cancer is about 2.
5 percent
.
Meghana S.
Pagadala, MD, of the Medical Scientist Training Program at the University of California, San Diego School of Medicine, said
Men at highest risk of metastatic or fatal prostate cancer are most likely to benefit
from screening or early detection.
The most common prostate cancer screening test is the prostate-specific antigen (PSA) test, which measures the level of a protein in the
blood.
Higher PSA levels in the blood may indicate prostate cancer, but a number of other factors can also affect PSA levels, screening everyone may lead to unnecessary biopsies, as well as the diagnosis and treatment
of low-grade cancers that do not pose a serious threat.
Tyler M.
Seibert, MD, assistant professor in the Department of Radiation Medicine and Applied Science, Radiology and Bioengineering at the University of California, San Diego School of Medicine, said
Current guidelines recommend that doctors discuss the benefits and harms
of screening with patients.
Guidelines recommend strengthening screening for high-risk men, but estimating a patient's risk of dying from prostate cancer is not straightforward for primary caregivers, and a more comprehensive and objective assessment
of each patient's risk is needed.
conclusion
risk of prostate cancer.
The median age at last follow-up was 69 years
.
In all cohort studies, PHS290 was associated with fatal prostate cancer (p<0.
001).
<b20> Comparing the 20% of men with the highest PHS290 levels to the 20% of men with the lowest PHS290 levels, the hazard ratio for fatal prostate cancer was 4.
42
.
When considering the risk factors recommended by the guidelines (family history, race, and ethnicity), PHS290 remains a strong independent predictor
of various metastatic and fatal prostate cancers.
prospect
Seibert, MD, said:
- PHS290 can stratify
the lifetime risk of prostate cancer, including metastatic and fatal cancer, in U.
S.
veterans of different ancestry. - Current clinical guidelines for determining individualized risk assessment focus on race, ethnicity, and family history
.
We demonstrated in this study that polygenic scores provide considerable information
based on a very large, diverse longitudinal cohort.
Patients and doctors can better understand who is at highest risk of aggressive prostate cancer
. - Based on a combination of ethnicity, family history, and genetics, men at high risk of prostate cancer may still develop false-positive or low-grade prostate cancer
on PSA tests.
Anyone who is screened for prostate cancer should be advised to use tools such as prostate MRI before a biopsy and should be actively monitored
if they have been diagnosed with low-grade cancer. - Predicting the genetic risk of fatal prostate cancer with PHS290 may inform individualized decision-making for prostate cancer screening
.
Click "Read Original" to get more clinical dry goods
